▶ 調査レポート

腎細胞がん治療薬の世界市場(~2026年)

• 英文タイトル:Global Renal Cell Carcinoma Drugs Market Insights and Forecast to 2026

QYResearchが調査・発行した産業分析レポートです。腎細胞がん治療薬の世界市場(~2026年) / Global Renal Cell Carcinoma Drugs Market Insights and Forecast to 2026 / MRC2-11QY09053資料のイメージです。• レポートコード:MRC2-11QY09053
• 出版社/出版日:QYResearch / 2020年11月25日
• レポート形態:英文、PDF、110ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医療、製薬
• 販売価格(消費税別)
  Single User¥417,300 (USD3,900)▷ お問い合わせ
  Multi User¥625,950 (USD5,850)▷ お問い合わせ
  Enterprise License¥834,600 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料は腎細胞がん治療薬のグローバル市場について調査・分析したレポートです。種類別(ソマトスタチン類似体、標的療法、化学療法)市場規模、用途別(病院、クリニック、腫瘍学センター)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別腎細胞がん治療薬の競争状況、市場シェア
・世界の腎細胞がん治療薬市場:種類別市場規模 2015年-2020年(ソマトスタチン類似体、標的療法、化学療法)
・世界の腎細胞がん治療薬市場:種類別市場規模予測 2021年-2026年(ソマトスタチン類似体、標的療法、化学療法)
・世界の腎細胞がん治療薬市場:用途別市場規模 2015年-2020年(病院、クリニック、腫瘍学センター)
・世界の腎細胞がん治療薬市場:用途別市場規模予測 2021年-2026年(病院、クリニック、腫瘍学センター)
・北米の腎細胞がん治療薬市場分析:米国、カナダ
・ヨーロッパの腎細胞がん治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの腎細胞がん治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の腎細胞がん治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの腎細胞がん治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Xiaflex、Novartis AG、Roche、Molecular Insight Pharmaceuticals、Callisto Pharmaceuticals
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.The drug is developed for fightting RCC.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Renal Cell Carcinoma Drugs in US$ by the following Product Segments: Somatostatin Analogs, Targeted Therapy, Chemotherapy
Company profiles are primarily based on public domain information including company
Novartis AG
Roche
Molecular Insight pharmaceuticals
Callisto Pharmaceuticals
Xiaflex

Market Analysis and Insights: Global Renal Cell Carcinoma Drugs Market
The global Renal Cell Carcinoma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Renal Cell Carcinoma Drugs Scope and Market Size
Renal Cell Carcinoma Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Renal Cell Carcinoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Renal Cell Carcinoma Drugs market is segmented into
Somatostatin Analogs
Targeted Therapy
Chemotherapy

Segment by Application, the Renal Cell Carcinoma Drugs market is segmented into
Hospital
Clinics
Oncology Centres

Regional and Country-level Analysis
The Renal Cell Carcinoma Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Renal Cell Carcinoma Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Renal Cell Carcinoma Drugs Market Share Analysis
Renal Cell Carcinoma Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Renal Cell Carcinoma Drugs business, the date to enter into the Renal Cell Carcinoma Drugs market, Renal Cell Carcinoma Drugs product introduction, recent developments, etc.

The major vendors covered:
Xiaflex
Novartis AG
Roche
Molecular Insight Pharmaceuticals
Callisto Pharmaceuticals

レポート目次

1 Study Coverage
1.1 Renal Cell Carcinoma Drugs Product Introduction
1.2 Market Segments
1.3 Key Renal Cell Carcinoma Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Renal Cell Carcinoma Drugs Market Size Growth Rate by Type
1.4.2 Somatostatin Analogs
1.4.3 Targeted Therapy
1.4.4 Chemotherapy
1.5 Market by Application
1.5.1 Global Renal Cell Carcinoma Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Oncology Centres
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Renal Cell Carcinoma Drugs Market Size, Estimates and Forecasts
2.1.1 Global Renal Cell Carcinoma Drugs Revenue 2015-2026
2.1.2 Global Renal Cell Carcinoma Drugs Sales 2015-2026
2.2 Global Renal Cell Carcinoma Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Renal Cell Carcinoma Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Renal Cell Carcinoma Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Renal Cell Carcinoma Drugs Competitor Landscape by Players
3.1 Renal Cell Carcinoma Drugs Sales by Manufacturers
3.1.1 Renal Cell Carcinoma Drugs Sales by Manufacturers (2015-2020)
3.1.2 Renal Cell Carcinoma Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Renal Cell Carcinoma Drugs Revenue by Manufacturers
3.2.1 Renal Cell Carcinoma Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Renal Cell Carcinoma Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Renal Cell Carcinoma Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Renal Cell Carcinoma Drugs Revenue in 2019
3.2.5 Global Renal Cell Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Renal Cell Carcinoma Drugs Price by Manufacturers
3.4 Renal Cell Carcinoma Drugs Manufacturing Base Distribution, Product Types
3.4.1 Renal Cell Carcinoma Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Renal Cell Carcinoma Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Renal Cell Carcinoma Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Renal Cell Carcinoma Drugs Market Size by Type (2015-2020)
4.1.1 Global Renal Cell Carcinoma Drugs Sales by Type (2015-2020)
4.1.2 Global Renal Cell Carcinoma Drugs Revenue by Type (2015-2020)
4.1.3 Renal Cell Carcinoma Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Renal Cell Carcinoma Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Renal Cell Carcinoma Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Renal Cell Carcinoma Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Renal Cell Carcinoma Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Renal Cell Carcinoma Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Renal Cell Carcinoma Drugs Market Size by Application (2015-2020)
5.1.1 Global Renal Cell Carcinoma Drugs Sales by Application (2015-2020)
5.1.2 Global Renal Cell Carcinoma Drugs Revenue by Application (2015-2020)
5.1.3 Renal Cell Carcinoma Drugs Price by Application (2015-2020)
5.2 Renal Cell Carcinoma Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Renal Cell Carcinoma Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Renal Cell Carcinoma Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Renal Cell Carcinoma Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Renal Cell Carcinoma Drugs by Country
6.1.1 North America Renal Cell Carcinoma Drugs Sales by Country
6.1.2 North America Renal Cell Carcinoma Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Renal Cell Carcinoma Drugs Market Facts & Figures by Type
6.3 North America Renal Cell Carcinoma Drugs Market Facts & Figures by Application

7 Europe
7.1 Europe Renal Cell Carcinoma Drugs by Country
7.1.1 Europe Renal Cell Carcinoma Drugs Sales by Country
7.1.2 Europe Renal Cell Carcinoma Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Renal Cell Carcinoma Drugs Market Facts & Figures by Type
7.3 Europe Renal Cell Carcinoma Drugs Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Renal Cell Carcinoma Drugs by Region
8.1.1 Asia Pacific Renal Cell Carcinoma Drugs Sales by Region
8.1.2 Asia Pacific Renal Cell Carcinoma Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Renal Cell Carcinoma Drugs Market Facts & Figures by Type
8.3 Asia Pacific Renal Cell Carcinoma Drugs Market Facts & Figures by Application

9 Latin America
9.1 Latin America Renal Cell Carcinoma Drugs by Country
9.1.1 Latin America Renal Cell Carcinoma Drugs Sales by Country
9.1.2 Latin America Renal Cell Carcinoma Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Renal Cell Carcinoma Drugs Market Facts & Figures by Type
9.3 Central & South America Renal Cell Carcinoma Drugs Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Renal Cell Carcinoma Drugs by Country
10.1.1 Middle East and Africa Renal Cell Carcinoma Drugs Sales by Country
10.1.2 Middle East and Africa Renal Cell Carcinoma Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Renal Cell Carcinoma Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Renal Cell Carcinoma Drugs Market Facts & Figures by Application

11 Company Profiles
11.1 Xiaflex
11.1.1 Xiaflex Corporation Information
11.1.2 Xiaflex Description and Business Overview
11.1.3 Xiaflex Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Xiaflex Renal Cell Carcinoma Drugs Products Offered
11.1.5 Xiaflex Related Developments
11.2 Novartis AG
11.2.1 Novartis AG Corporation Information
11.2.2 Novartis AG Description and Business Overview
11.2.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Novartis AG Renal Cell Carcinoma Drugs Products Offered
11.2.5 Novartis AG Related Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Description and Business Overview
11.3.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Roche Renal Cell Carcinoma Drugs Products Offered
11.3.5 Roche Related Developments
11.4 Molecular Insight Pharmaceuticals
11.4.1 Molecular Insight Pharmaceuticals Corporation Information
11.4.2 Molecular Insight Pharmaceuticals Description and Business Overview
11.4.3 Molecular Insight Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Molecular Insight Pharmaceuticals Renal Cell Carcinoma Drugs Products Offered
11.4.5 Molecular Insight Pharmaceuticals Related Developments
11.5 Callisto Pharmaceuticals
11.5.1 Callisto Pharmaceuticals Corporation Information
11.5.2 Callisto Pharmaceuticals Description and Business Overview
11.5.3 Callisto Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Callisto Pharmaceuticals Renal Cell Carcinoma Drugs Products Offered
11.5.5 Callisto Pharmaceuticals Related Developments
11.1 Xiaflex
11.1.1 Xiaflex Corporation Information
11.1.2 Xiaflex Description and Business Overview
11.1.3 Xiaflex Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Xiaflex Renal Cell Carcinoma Drugs Products Offered
11.1.5 Xiaflex Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Renal Cell Carcinoma Drugs Market Estimates and Projections by Region
12.1.1 Global Renal Cell Carcinoma Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Renal Cell Carcinoma Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Renal Cell Carcinoma Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Renal Cell Carcinoma Drugs Sales Forecast (2021-2026)
12.2.2 North America: Renal Cell Carcinoma Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Renal Cell Carcinoma Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Renal Cell Carcinoma Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Renal Cell Carcinoma Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Renal Cell Carcinoma Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Renal Cell Carcinoma Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Renal Cell Carcinoma Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Renal Cell Carcinoma Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Renal Cell Carcinoma Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Renal Cell Carcinoma Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Renal Cell Carcinoma Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Renal Cell Carcinoma Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Renal Cell Carcinoma Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Renal Cell Carcinoma Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Renal Cell Carcinoma Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Renal Cell Carcinoma Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Renal Cell Carcinoma Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Renal Cell Carcinoma Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Renal Cell Carcinoma Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Renal Cell Carcinoma Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Renal Cell Carcinoma Drugs Market Segments
Table 2. Ranking of Global Top Renal Cell Carcinoma Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Renal Cell Carcinoma Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Somatostatin Analogs
Table 5. Major Manufacturers of Targeted Therapy
Table 6. Major Manufacturers of Chemotherapy
Table 7. Global Renal Cell Carcinoma Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global Renal Cell Carcinoma Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global Renal Cell Carcinoma Drugs Sales by Regions 2015-2020 (K Units)
Table 10. Global Renal Cell Carcinoma Drugs Sales Market Share by Regions (2015-2020)
Table 11. Global Renal Cell Carcinoma Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Renal Cell Carcinoma Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 13. Global Renal Cell Carcinoma Drugs Sales Share by Manufacturers (2015-2020)
Table 14. Global Renal Cell Carcinoma Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Renal Cell Carcinoma Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Renal Cell Carcinoma Drugs as of 2019)
Table 16. Renal Cell Carcinoma Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Renal Cell Carcinoma Drugs Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Renal Cell Carcinoma Drugs Price (2015-2020) (USD/Unit)
Table 19. Renal Cell Carcinoma Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Renal Cell Carcinoma Drugs Product Type
Table 21. Date of International Manufacturers Enter into Renal Cell Carcinoma Drugs Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Renal Cell Carcinoma Drugs Sales by Type (2015-2020) (K Units)
Table 24. Global Renal Cell Carcinoma Drugs Sales Share by Type (2015-2020)
Table 25. Global Renal Cell Carcinoma Drugs Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Renal Cell Carcinoma Drugs Revenue Share by Type (2015-2020)
Table 27. Renal Cell Carcinoma Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 28. Global Renal Cell Carcinoma Drugs Sales by Application (2015-2020) (K Units)
Table 29. Global Renal Cell Carcinoma Drugs Sales Share by Application (2015-2020)
Table 30. North America Renal Cell Carcinoma Drugs Sales by Country (2015-2020) (K Units)
Table 31. North America Renal Cell Carcinoma Drugs Sales Market Share by Country (2015-2020)
Table 32. North America Renal Cell Carcinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Renal Cell Carcinoma Drugs Revenue Market Share by Country (2015-2020)
Table 34. North America Renal Cell Carcinoma Drugs Sales by Type (2015-2020) (K Units)
Table 35. North America Renal Cell Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 36. North America Renal Cell Carcinoma Drugs Sales by Application (2015-2020) (K Units)
Table 37. North America Renal Cell Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 38. Europe Renal Cell Carcinoma Drugs Sales by Country (2015-2020) (K Units)
Table 39. Europe Renal Cell Carcinoma Drugs Sales Market Share by Country (2015-2020)
Table 40. Europe Renal Cell Carcinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Renal Cell Carcinoma Drugs Revenue Market Share by Country (2015-2020)
Table 42. Europe Renal Cell Carcinoma Drugs Sales by Type (2015-2020) (K Units)
Table 43. Europe Renal Cell Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 44. Europe Renal Cell Carcinoma Drugs Sales by Application (2015-2020) (K Units)
Table 45. Europe Renal Cell Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Renal Cell Carcinoma Drugs Sales by Region (2015-2020) (K Units)
Table 47. Asia Pacific Renal Cell Carcinoma Drugs Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Renal Cell Carcinoma Drugs Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Renal Cell Carcinoma Drugs Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Renal Cell Carcinoma Drugs Sales by Type (2015-2020) (K Units)
Table 51. Asia Pacific Renal Cell Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Renal Cell Carcinoma Drugs Sales by Application (2015-2020) (K Units)
Table 53. Asia Pacific Renal Cell Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 54. Latin America Renal Cell Carcinoma Drugs Sales by Country (2015-2020) (K Units)
Table 55. Latin America Renal Cell Carcinoma Drugs Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Renal Cell Carcinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Renal Cell Carcinoma Drugs Revenue Market Share by Country (2015-2020)
Table 58. Latin America Renal Cell Carcinoma Drugs Sales by Type (2015-2020) (K Units)
Table 59. Latin America Renal Cell Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 60. Latin America Renal Cell Carcinoma Drugs Sales by Application (2015-2020) (K Units)
Table 61. Latin America Renal Cell Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Renal Cell Carcinoma Drugs Sales by Country (2015-2020) (K Units)
Table 63. Middle East and Africa Renal Cell Carcinoma Drugs Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Renal Cell Carcinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Renal Cell Carcinoma Drugs Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Renal Cell Carcinoma Drugs Sales by Type (2015-2020) (K Units)
Table 67. Middle East and Africa Renal Cell Carcinoma Drugs Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Renal Cell Carcinoma Drugs Sales by Application (2015-2020) (K Units)
Table 69. Middle East and Africa Renal Cell Carcinoma Drugs Sales Market Share by Application (2015-2020)
Table 70. Xiaflex Corporation Information
Table 71. Xiaflex Description and Major Businesses
Table 72. Xiaflex Renal Cell Carcinoma Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 73. Xiaflex Product
Table 74. Xiaflex Recent Development
Table 75. Novartis AG Corporation Information
Table 76. Novartis AG Description and Major Businesses
Table 77. Novartis AG Renal Cell Carcinoma Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Novartis AG Product
Table 79. Novartis AG Recent Development
Table 80. Roche Corporation Information
Table 81. Roche Description and Major Businesses
Table 82. Roche Renal Cell Carcinoma Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Roche Product
Table 84. Roche Recent Development
Table 85. Molecular Insight Pharmaceuticals Corporation Information
Table 86. Molecular Insight Pharmaceuticals Description and Major Businesses
Table 87. Molecular Insight Pharmaceuticals Renal Cell Carcinoma Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Molecular Insight Pharmaceuticals Product
Table 89. Molecular Insight Pharmaceuticals Recent Development
Table 90. Callisto Pharmaceuticals Corporation Information
Table 91. Callisto Pharmaceuticals Description and Major Businesses
Table 92. Callisto Pharmaceuticals Renal Cell Carcinoma Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Callisto Pharmaceuticals Product
Table 94. Callisto Pharmaceuticals Recent Development
Table 95. Global Renal Cell Carcinoma Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 96. Global Renal Cell Carcinoma Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 97. Global Renal Cell Carcinoma Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 98. Global Renal Cell Carcinoma Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 99. North America: Renal Cell Carcinoma Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 100. North America: Renal Cell Carcinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 101. Europe: Renal Cell Carcinoma Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 102. Europe: Renal Cell Carcinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Asia Pacific: Renal Cell Carcinoma Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 104. Asia Pacific: Renal Cell Carcinoma Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 105. Latin America: Renal Cell Carcinoma Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 106. Latin America: Renal Cell Carcinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Middle East and Africa: Renal Cell Carcinoma Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 108. Middle East and Africa: Renal Cell Carcinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 110. Key Challenges
Table 111. Market Risks
Table 112. Main Points Interviewed from Key Renal Cell Carcinoma Drugs Players
Table 113. Renal Cell Carcinoma Drugs Customers List
Table 114. Renal Cell Carcinoma Drugs Distributors List
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Renal Cell Carcinoma Drugs Product Picture
Figure 2. Global Renal Cell Carcinoma Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Somatostatin Analogs Product Picture
Figure 4. Targeted Therapy Product Picture
Figure 5. Chemotherapy Product Picture
Figure 6. Global Renal Cell Carcinoma Drugs Sales Market Share by Application in 2020 & 2026
Figure 7. Hospital
Figure 8. Clinics
Figure 9. Oncology Centres
Figure 10. Renal Cell Carcinoma Drugs Report Years Considered
Figure 11. Global Renal Cell Carcinoma Drugs Market Size 2015-2026 (US$ Million)
Figure 12. Global Renal Cell Carcinoma Drugs Sales 2015-2026 (K Units)
Figure 13. Global Renal Cell Carcinoma Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Renal Cell Carcinoma Drugs Sales Market Share by Region (2015-2020)
Figure 15. Global Renal Cell Carcinoma Drugs Sales Market Share by Region in 2019
Figure 16. Global Renal Cell Carcinoma Drugs Revenue Market Share by Region (2015-2020)
Figure 17. Global Renal Cell Carcinoma Drugs Revenue Market Share by Region in 2019
Figure 18. Global Renal Cell Carcinoma Drugs Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Renal Cell Carcinoma Drugs Revenue in 2019
Figure 20. Renal Cell Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Renal Cell Carcinoma Drugs Sales Market Share by Type (2015-2020)
Figure 22. Global Renal Cell Carcinoma Drugs Sales Market Share by Type in 2019
Figure 23. Global Renal Cell Carcinoma Drugs Revenue Market Share by Type (2015-2020)
Figure 24. Global Renal Cell Carcinoma Drugs Revenue Market Share by Type in 2019
Figure 25. Global Renal Cell Carcinoma Drugs Market Share by Price Range (2015-2020)
Figure 26. Global Renal Cell Carcinoma Drugs Sales Market Share by Application (2015-2020)
Figure 27. Global Renal Cell Carcinoma Drugs Sales Market Share by Application in 2019
Figure 28. Global Renal Cell Carcinoma Drugs Revenue Market Share by Application (2015-2020)
Figure 29. Global Renal Cell Carcinoma Drugs Revenue Market Share by Application in 2019
Figure 30. North America Renal Cell Carcinoma Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 31. North America Renal Cell Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Renal Cell Carcinoma Drugs Sales Market Share by Country in 2019
Figure 33. North America Renal Cell Carcinoma Drugs Revenue Market Share by Country in 2019
Figure 34. U.S. Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 35. U.S. Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 37. Canada Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Renal Cell Carcinoma Drugs Market Share by Type in 2019
Figure 39. North America Renal Cell Carcinoma Drugs Market Share by Application in 2019
Figure 40. Europe Renal Cell Carcinoma Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 41. Europe Renal Cell Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Renal Cell Carcinoma Drugs Sales Market Share by Country in 2019
Figure 43. Europe Renal Cell Carcinoma Drugs Revenue Market Share by Country in 2019
Figure 44. Germany Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 45. Germany Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 47. France Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 49. U.K. Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 51. Italy Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 53. Russia Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Renal Cell Carcinoma Drugs Market Share by Type in 2019
Figure 55. Europe Renal Cell Carcinoma Drugs Market Share by Application in 2019
Figure 56. Asia Pacific Renal Cell Carcinoma Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 57. Asia Pacific Renal Cell Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Renal Cell Carcinoma Drugs Sales Market Share by Region in 2019
Figure 59. Asia Pacific Renal Cell Carcinoma Drugs Revenue Market Share by Region in 2019
Figure 60. China Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 61. China Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 63. Japan Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 65. South Korea Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 67. India Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 69. Australia Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 71. Taiwan Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 73. Indonesia Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 75. Thailand Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 77. Malaysia Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 79. Philippines Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 81. Vietnam Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Renal Cell Carcinoma Drugs Market Share by Type in 2019
Figure 83. Asia Pacific Renal Cell Carcinoma Drugs Market Share by Application in 2019
Figure 84. Latin America Renal Cell Carcinoma Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 85. Latin America Renal Cell Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Renal Cell Carcinoma Drugs Sales Market Share by Country in 2019
Figure 87. Latin America Renal Cell Carcinoma Drugs Revenue Market Share by Country in 2019
Figure 88. Mexico Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 89. Mexico Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 91. Brazil Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 93. Argentina Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Renal Cell Carcinoma Drugs Market Share by Type in 2019
Figure 95. Latin America Renal Cell Carcinoma Drugs Market Share by Application in 2019
Figure 96. Middle East and Africa Renal Cell Carcinoma Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 97. Middle East and Africa Renal Cell Carcinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Renal Cell Carcinoma Drugs Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Renal Cell Carcinoma Drugs Revenue Market Share by Country in 2019
Figure 100. Turkey Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 101. Turkey Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 103. Saudi Arabia Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Renal Cell Carcinoma Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 105. U.A.E Renal Cell Carcinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Renal Cell Carcinoma Drugs Market Share by Type in 2019
Figure 107. Middle East and Africa Renal Cell Carcinoma Drugs Market Share by Application in 2019
Figure 108. North America Renal Cell Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. North America Renal Cell Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Renal Cell Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Europe Renal Cell Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Renal Cell Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Asia Pacific Renal Cell Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Renal Cell Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Latin America Renal Cell Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Renal Cell Carcinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Middle East and Africa Renal Cell Carcinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed